In this article with Pharmaceutical Executive, uMed CEO & Founder, Dr Matt Wilson, discusses the need for robust evidence that goes beyond just routinely collected data and that accurately reflects the diverse patient populations affected by obesity.By leveraging advanced data collection methods, including patient-reported outcomes and digital health tools, the healthcare industry can build stronger evidence, enhancing the personalization and effectiveness of obesity treatments for broader populations. This shift promises to bridge gaps in clinical research and support better decision-making across the pharmaceutical and healthcare sectors.

‍